nodes	percent_of_prediction	percent_of_DWPC	metapath
Clomipramine—GSTP1—urinary bladder cancer	0.384	1	CbGaD
Clomipramine—GSTP1—Carboplatin—urinary bladder cancer	0.11	0.265	CbGbCtD
Clomipramine—GSTP1—Cisplatin—urinary bladder cancer	0.0936	0.227	CbGbCtD
Clomipramine—GSTP1—Etoposide—urinary bladder cancer	0.092	0.223	CbGbCtD
Clomipramine—ABCB1—Mitomycin—urinary bladder cancer	0.0293	0.0709	CbGbCtD
Clomipramine—ALB—Fluorouracil—urinary bladder cancer	0.0138	0.0334	CbGbCtD
Clomipramine—CYP3A4—Thiotepa—urinary bladder cancer	0.0133	0.0322	CbGbCtD
Clomipramine—ABCB1—Gemcitabine—urinary bladder cancer	0.00843	0.0204	CbGbCtD
Clomipramine—CYP1A2—Fluorouracil—urinary bladder cancer	0.00825	0.02	CbGbCtD
Clomipramine—ALB—Methotrexate—urinary bladder cancer	0.0076	0.0184	CbGbCtD
Clomipramine—CYP1A2—Etoposide—urinary bladder cancer	0.00688	0.0167	CbGbCtD
Clomipramine—ABCB1—Cisplatin—urinary bladder cancer	0.00613	0.0148	CbGbCtD
Clomipramine—ABCB1—Etoposide—urinary bladder cancer	0.00602	0.0146	CbGbCtD
Clomipramine—ABCB1—Doxorubicin—urinary bladder cancer	0.00411	0.00994	CbGbCtD
Clomipramine—ABCB1—Methotrexate—urinary bladder cancer	0.00398	0.00963	CbGbCtD
Clomipramine—CYP2D6—Doxorubicin—urinary bladder cancer	0.00387	0.00937	CbGbCtD
Clomipramine—CYP3A4—Etoposide—urinary bladder cancer	0.00361	0.00873	CbGbCtD
Clomipramine—GSTP1—urine—urinary bladder cancer	0.00297	0.106	CbGeAlD
Clomipramine—CYP3A4—Doxorubicin—urinary bladder cancer	0.00246	0.00596	CbGbCtD
Clomipramine—CYP2C19—urine—urinary bladder cancer	0.00205	0.0728	CbGeAlD
Clomipramine—CYP1A2—urine—urinary bladder cancer	0.00167	0.0595	CbGeAlD
Clomipramine—HTR2A—urine—urinary bladder cancer	0.00131	0.0465	CbGeAlD
Clomipramine—Olopatadine—S100B—urinary bladder cancer	0.00129	1	CrCbGaD
Clomipramine—CYP3A4—urine—urinary bladder cancer	0.00121	0.043	CbGeAlD
Clomipramine—CYP2D6—urine—urinary bladder cancer	0.00119	0.0423	CbGeAlD
Clomipramine—GSTP1—prostate gland—urinary bladder cancer	0.00107	0.0379	CbGeAlD
Clomipramine—GSTP1—seminal vesicle—urinary bladder cancer	0.000902	0.0321	CbGeAlD
Clomipramine—GSTP1—epithelium—urinary bladder cancer	0.000784	0.0278	CbGeAlD
Clomipramine—GSTP1—smooth muscle tissue—urinary bladder cancer	0.000755	0.0268	CbGeAlD
Clomipramine—GSTP1—renal system—urinary bladder cancer	0.000727	0.0258	CbGeAlD
Clomipramine—GSTP1—urethra—urinary bladder cancer	0.000714	0.0254	CbGeAlD
Clomipramine—HTR2B—smooth muscle tissue—urinary bladder cancer	0.000623	0.0221	CbGeAlD
Clomipramine—GSTP1—female reproductive system—urinary bladder cancer	0.000582	0.0207	CbGeAlD
Clomipramine—ADRA2A—prostate gland—urinary bladder cancer	0.000552	0.0196	CbGeAlD
Clomipramine—GSTP1—vagina—urinary bladder cancer	0.000526	0.0187	CbGeAlD
Clomipramine—HTR2C—female reproductive system—urinary bladder cancer	0.000511	0.0182	CbGeAlD
Clomipramine—SLC6A4—female reproductive system—urinary bladder cancer	0.000484	0.0172	CbGeAlD
Clomipramine—HTR2B—female reproductive system—urinary bladder cancer	0.00048	0.0171	CbGeAlD
Clomipramine—HRH2—lymph node—urinary bladder cancer	0.000473	0.0168	CbGeAlD
Clomipramine—ADRA2A—seminal vesicle—urinary bladder cancer	0.000467	0.0166	CbGeAlD
Clomipramine—HTR2B—vagina—urinary bladder cancer	0.000434	0.0154	CbGeAlD
Clomipramine—SLC6A2—female reproductive system—urinary bladder cancer	0.000426	0.0152	CbGeAlD
Clomipramine—CYP1A2—renal system—urinary bladder cancer	0.000409	0.0145	CbGeAlD
Clomipramine—ADRA2A—urethra—urinary bladder cancer	0.00037	0.0131	CbGeAlD
Clomipramine—CYP2C19—vagina—urinary bladder cancer	0.000363	0.0129	CbGeAlD
Clomipramine—HTR2A—epithelium—urinary bladder cancer	0.000345	0.0123	CbGeAlD
Clomipramine—GSTP1—lymph node—urinary bladder cancer	0.000341	0.0121	CbGeAlD
Clomipramine—HTR2A—smooth muscle tissue—urinary bladder cancer	0.000332	0.0118	CbGeAlD
Clomipramine—HTR2A—renal system—urinary bladder cancer	0.00032	0.0114	CbGeAlD
Clomipramine—ABCB1—prostate gland—urinary bladder cancer	0.000308	0.0109	CbGeAlD
Clomipramine—ADRA2A—female reproductive system—urinary bladder cancer	0.000301	0.0107	CbGeAlD
Clomipramine—CYP3A4—renal system—urinary bladder cancer	0.000296	0.0105	CbGeAlD
Clomipramine—ALB—lymph node—urinary bladder cancer	0.000292	0.0104	CbGeAlD
Clomipramine—CYP2D6—renal system—urinary bladder cancer	0.000292	0.0104	CbGeAlD
Clomipramine—HTR2B—lymph node—urinary bladder cancer	0.000281	0.00998	CbGeAlD
Clomipramine—ADRA2A—vagina—urinary bladder cancer	0.000273	0.00969	CbGeAlD
Clomipramine—ABCB1—seminal vesicle—urinary bladder cancer	0.00026	0.00925	CbGeAlD
Clomipramine—HTR2A—female reproductive system—urinary bladder cancer	0.000256	0.00911	CbGeAlD
Clomipramine—SLC6A2—lymph node—urinary bladder cancer	0.000249	0.00887	CbGeAlD
Clomipramine—CYP3A4—female reproductive system—urinary bladder cancer	0.000237	0.00843	CbGeAlD
Clomipramine—CYP2D6—female reproductive system—urinary bladder cancer	0.000234	0.0083	CbGeAlD
Clomipramine—HTR2A—vagina—urinary bladder cancer	0.000232	0.00824	CbGeAlD
Clomipramine—ABCB1—epithelium—urinary bladder cancer	0.000226	0.00804	CbGeAlD
Clomipramine—ABCB1—renal system—urinary bladder cancer	0.00021	0.00745	CbGeAlD
Clomipramine—ABCB1—urethra—urinary bladder cancer	0.000206	0.00732	CbGeAlD
Clomipramine—ADRA2A—lymph node—urinary bladder cancer	0.000176	0.00627	CbGeAlD
Clomipramine—ABCB1—female reproductive system—urinary bladder cancer	0.000168	0.00597	CbGeAlD
Clomipramine—ABCB1—vagina—urinary bladder cancer	0.000152	0.0054	CbGeAlD
Clomipramine—ABCB1—lymph node—urinary bladder cancer	9.83e-05	0.00349	CbGeAlD
Clomipramine—Sweating—Doxorubicin—urinary bladder cancer	5.26e-05	0.000422	CcSEcCtD
Clomipramine—Urinary tract disorder—Epirubicin—urinary bladder cancer	5.26e-05	0.000422	CcSEcCtD
Clomipramine—Haematuria—Doxorubicin—urinary bladder cancer	5.23e-05	0.00042	CcSEcCtD
Clomipramine—Connective tissue disorder—Epirubicin—urinary bladder cancer	5.23e-05	0.00042	CcSEcCtD
Clomipramine—Urethral disorder—Epirubicin—urinary bladder cancer	5.22e-05	0.000419	CcSEcCtD
Clomipramine—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	5.19e-05	0.000416	CcSEcCtD
Clomipramine—Epistaxis—Doxorubicin—urinary bladder cancer	5.18e-05	0.000415	CcSEcCtD
Clomipramine—Angiopathy—Methotrexate—urinary bladder cancer	5.16e-05	0.000414	CcSEcCtD
Clomipramine—Sinusitis—Doxorubicin—urinary bladder cancer	5.15e-05	0.000413	CcSEcCtD
Clomipramine—Immune system disorder—Methotrexate—urinary bladder cancer	5.14e-05	0.000412	CcSEcCtD
Clomipramine—Dizziness—Fluorouracil—urinary bladder cancer	5.14e-05	0.000412	CcSEcCtD
Clomipramine—Visual impairment—Epirubicin—urinary bladder cancer	5.13e-05	0.000412	CcSEcCtD
Clomipramine—Mediastinal disorder—Methotrexate—urinary bladder cancer	5.13e-05	0.000411	CcSEcCtD
Clomipramine—Agranulocytosis—Doxorubicin—urinary bladder cancer	5.12e-05	0.000411	CcSEcCtD
Clomipramine—Chills—Methotrexate—urinary bladder cancer	5.11e-05	0.00041	CcSEcCtD
Clomipramine—Diarrhoea—Cisplatin—urinary bladder cancer	5.04e-05	0.000404	CcSEcCtD
Clomipramine—Alopecia—Methotrexate—urinary bladder cancer	5.03e-05	0.000403	CcSEcCtD
Clomipramine—Vomiting—Gemcitabine—urinary bladder cancer	5.03e-05	0.000403	CcSEcCtD
Clomipramine—Bradycardia—Doxorubicin—urinary bladder cancer	5.02e-05	0.000402	CcSEcCtD
Clomipramine—Mental disorder—Methotrexate—urinary bladder cancer	4.99e-05	0.0004	CcSEcCtD
Clomipramine—Rash—Gemcitabine—urinary bladder cancer	4.99e-05	0.0004	CcSEcCtD
Clomipramine—Dermatitis—Gemcitabine—urinary bladder cancer	4.98e-05	0.000399	CcSEcCtD
Clomipramine—Eye disorder—Epirubicin—urinary bladder cancer	4.98e-05	0.000399	CcSEcCtD
Clomipramine—Hypersensitivity—Etoposide—urinary bladder cancer	4.97e-05	0.000399	CcSEcCtD
Clomipramine—Tinnitus—Epirubicin—urinary bladder cancer	4.97e-05	0.000398	CcSEcCtD
Clomipramine—Malnutrition—Methotrexate—urinary bladder cancer	4.95e-05	0.000397	CcSEcCtD
Clomipramine—Headache—Gemcitabine—urinary bladder cancer	4.95e-05	0.000397	CcSEcCtD
Clomipramine—Flushing—Epirubicin—urinary bladder cancer	4.94e-05	0.000396	CcSEcCtD
Clomipramine—Cardiac disorder—Epirubicin—urinary bladder cancer	4.94e-05	0.000396	CcSEcCtD
Clomipramine—Vomiting—Fluorouracil—urinary bladder cancer	4.94e-05	0.000396	CcSEcCtD
Clomipramine—Rhinitis—Doxorubicin—urinary bladder cancer	4.94e-05	0.000396	CcSEcCtD
Clomipramine—Hepatitis—Doxorubicin—urinary bladder cancer	4.93e-05	0.000395	CcSEcCtD
Clomipramine—Hypoaesthesia—Doxorubicin—urinary bladder cancer	4.9e-05	0.000393	CcSEcCtD
Clomipramine—Rash—Fluorouracil—urinary bladder cancer	4.9e-05	0.000393	CcSEcCtD
Clomipramine—Dermatitis—Fluorouracil—urinary bladder cancer	4.9e-05	0.000393	CcSEcCtD
Clomipramine—Pharyngitis—Doxorubicin—urinary bladder cancer	4.89e-05	0.000392	CcSEcCtD
Clomipramine—Headache—Fluorouracil—urinary bladder cancer	4.87e-05	0.000391	CcSEcCtD
Clomipramine—Urinary tract disorder—Doxorubicin—urinary bladder cancer	4.87e-05	0.00039	CcSEcCtD
Clomipramine—Dysgeusia—Methotrexate—urinary bladder cancer	4.85e-05	0.000389	CcSEcCtD
Clomipramine—Asthenia—Etoposide—urinary bladder cancer	4.84e-05	0.000388	CcSEcCtD
Clomipramine—Connective tissue disorder—Doxorubicin—urinary bladder cancer	4.84e-05	0.000388	CcSEcCtD
Clomipramine—Angiopathy—Epirubicin—urinary bladder cancer	4.83e-05	0.000388	CcSEcCtD
Clomipramine—Urethral disorder—Doxorubicin—urinary bladder cancer	4.83e-05	0.000387	CcSEcCtD
Clomipramine—Immune system disorder—Epirubicin—urinary bladder cancer	4.81e-05	0.000386	CcSEcCtD
Clomipramine—Mediastinal disorder—Epirubicin—urinary bladder cancer	4.8e-05	0.000385	CcSEcCtD
Clomipramine—Back pain—Methotrexate—urinary bladder cancer	4.79e-05	0.000384	CcSEcCtD
Clomipramine—Chills—Epirubicin—urinary bladder cancer	4.78e-05	0.000383	CcSEcCtD
Clomipramine—Pruritus—Etoposide—urinary bladder cancer	4.78e-05	0.000383	CcSEcCtD
Clomipramine—Arrhythmia—Epirubicin—urinary bladder cancer	4.76e-05	0.000382	CcSEcCtD
Clomipramine—Visual impairment—Doxorubicin—urinary bladder cancer	4.75e-05	0.000381	CcSEcCtD
Clomipramine—Alopecia—Epirubicin—urinary bladder cancer	4.71e-05	0.000377	CcSEcCtD
Clomipramine—Nausea—Gemcitabine—urinary bladder cancer	4.7e-05	0.000377	CcSEcCtD
Clomipramine—Vomiting—Cisplatin—urinary bladder cancer	4.69e-05	0.000376	CcSEcCtD
Clomipramine—Vision blurred—Methotrexate—urinary bladder cancer	4.67e-05	0.000374	CcSEcCtD
Clomipramine—Mental disorder—Epirubicin—urinary bladder cancer	4.67e-05	0.000374	CcSEcCtD
Clomipramine—Rash—Cisplatin—urinary bladder cancer	4.65e-05	0.000373	CcSEcCtD
Clomipramine—Dermatitis—Cisplatin—urinary bladder cancer	4.64e-05	0.000372	CcSEcCtD
Clomipramine—Malnutrition—Epirubicin—urinary bladder cancer	4.64e-05	0.000372	CcSEcCtD
Clomipramine—Diarrhoea—Etoposide—urinary bladder cancer	4.62e-05	0.00037	CcSEcCtD
Clomipramine—Nausea—Fluorouracil—urinary bladder cancer	4.62e-05	0.00037	CcSEcCtD
Clomipramine—Eye disorder—Doxorubicin—urinary bladder cancer	4.61e-05	0.000369	CcSEcCtD
Clomipramine—Ill-defined disorder—Methotrexate—urinary bladder cancer	4.6e-05	0.000369	CcSEcCtD
Clomipramine—Tinnitus—Doxorubicin—urinary bladder cancer	4.6e-05	0.000368	CcSEcCtD
Clomipramine—Anaemia—Methotrexate—urinary bladder cancer	4.58e-05	0.000367	CcSEcCtD
Clomipramine—Flushing—Doxorubicin—urinary bladder cancer	4.57e-05	0.000367	CcSEcCtD
Clomipramine—Cardiac disorder—Doxorubicin—urinary bladder cancer	4.57e-05	0.000367	CcSEcCtD
Clomipramine—Flatulence—Epirubicin—urinary bladder cancer	4.57e-05	0.000366	CcSEcCtD
Clomipramine—Tension—Epirubicin—urinary bladder cancer	4.55e-05	0.000365	CcSEcCtD
Clomipramine—Dysgeusia—Epirubicin—urinary bladder cancer	4.54e-05	0.000364	CcSEcCtD
Clomipramine—Nervousness—Epirubicin—urinary bladder cancer	4.5e-05	0.000361	CcSEcCtD
Clomipramine—Back pain—Epirubicin—urinary bladder cancer	4.49e-05	0.00036	CcSEcCtD
Clomipramine—Angiopathy—Doxorubicin—urinary bladder cancer	4.47e-05	0.000359	CcSEcCtD
Clomipramine—Malaise—Methotrexate—urinary bladder cancer	4.47e-05	0.000358	CcSEcCtD
Clomipramine—Dizziness—Etoposide—urinary bladder cancer	4.46e-05	0.000358	CcSEcCtD
Clomipramine—Muscle spasms—Epirubicin—urinary bladder cancer	4.46e-05	0.000357	CcSEcCtD
Clomipramine—Immune system disorder—Doxorubicin—urinary bladder cancer	4.45e-05	0.000357	CcSEcCtD
Clomipramine—Vertigo—Methotrexate—urinary bladder cancer	4.45e-05	0.000357	CcSEcCtD
Clomipramine—Mediastinal disorder—Doxorubicin—urinary bladder cancer	4.44e-05	0.000356	CcSEcCtD
Clomipramine—Leukopenia—Methotrexate—urinary bladder cancer	4.44e-05	0.000356	CcSEcCtD
Clomipramine—Chills—Doxorubicin—urinary bladder cancer	4.42e-05	0.000355	CcSEcCtD
Clomipramine—Arrhythmia—Doxorubicin—urinary bladder cancer	4.4e-05	0.000353	CcSEcCtD
Clomipramine—Nausea—Cisplatin—urinary bladder cancer	4.38e-05	0.000351	CcSEcCtD
Clomipramine—Vision blurred—Epirubicin—urinary bladder cancer	4.37e-05	0.00035	CcSEcCtD
Clomipramine—Alopecia—Doxorubicin—urinary bladder cancer	4.36e-05	0.000349	CcSEcCtD
Clomipramine—Cough—Methotrexate—urinary bladder cancer	4.32e-05	0.000347	CcSEcCtD
Clomipramine—Mental disorder—Doxorubicin—urinary bladder cancer	4.32e-05	0.000346	CcSEcCtD
Clomipramine—Ill-defined disorder—Epirubicin—urinary bladder cancer	4.3e-05	0.000345	CcSEcCtD
Clomipramine—Convulsion—Methotrexate—urinary bladder cancer	4.29e-05	0.000344	CcSEcCtD
Clomipramine—Vomiting—Etoposide—urinary bladder cancer	4.29e-05	0.000344	CcSEcCtD
Clomipramine—Malnutrition—Doxorubicin—urinary bladder cancer	4.29e-05	0.000344	CcSEcCtD
Clomipramine—Anaemia—Epirubicin—urinary bladder cancer	4.29e-05	0.000344	CcSEcCtD
Clomipramine—Agitation—Epirubicin—urinary bladder cancer	4.26e-05	0.000342	CcSEcCtD
Clomipramine—Rash—Etoposide—urinary bladder cancer	4.26e-05	0.000341	CcSEcCtD
Clomipramine—Dermatitis—Etoposide—urinary bladder cancer	4.25e-05	0.000341	CcSEcCtD
Clomipramine—Headache—Etoposide—urinary bladder cancer	4.23e-05	0.000339	CcSEcCtD
Clomipramine—Flatulence—Doxorubicin—urinary bladder cancer	4.23e-05	0.000339	CcSEcCtD
Clomipramine—Arthralgia—Methotrexate—urinary bladder cancer	4.22e-05	0.000338	CcSEcCtD
Clomipramine—Chest pain—Methotrexate—urinary bladder cancer	4.22e-05	0.000338	CcSEcCtD
Clomipramine—Myalgia—Methotrexate—urinary bladder cancer	4.22e-05	0.000338	CcSEcCtD
Clomipramine—Tension—Doxorubicin—urinary bladder cancer	4.21e-05	0.000338	CcSEcCtD
Clomipramine—Dysgeusia—Doxorubicin—urinary bladder cancer	4.2e-05	0.000337	CcSEcCtD
Clomipramine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	4.19e-05	0.000336	CcSEcCtD
Clomipramine—Malaise—Epirubicin—urinary bladder cancer	4.18e-05	0.000335	CcSEcCtD
Clomipramine—Discomfort—Methotrexate—urinary bladder cancer	4.17e-05	0.000334	CcSEcCtD
Clomipramine—Nervousness—Doxorubicin—urinary bladder cancer	4.17e-05	0.000334	CcSEcCtD
Clomipramine—Vertigo—Epirubicin—urinary bladder cancer	4.17e-05	0.000334	CcSEcCtD
Clomipramine—Syncope—Epirubicin—urinary bladder cancer	4.16e-05	0.000333	CcSEcCtD
Clomipramine—Leukopenia—Epirubicin—urinary bladder cancer	4.15e-05	0.000333	CcSEcCtD
Clomipramine—Back pain—Doxorubicin—urinary bladder cancer	4.15e-05	0.000333	CcSEcCtD
Clomipramine—Muscle spasms—Doxorubicin—urinary bladder cancer	4.12e-05	0.000331	CcSEcCtD
Clomipramine—Palpitations—Epirubicin—urinary bladder cancer	4.1e-05	0.000329	CcSEcCtD
Clomipramine—Confusional state—Methotrexate—urinary bladder cancer	4.08e-05	0.000327	CcSEcCtD
Clomipramine—Loss of consciousness—Epirubicin—urinary bladder cancer	4.08e-05	0.000327	CcSEcCtD
Clomipramine—Cough—Epirubicin—urinary bladder cancer	4.05e-05	0.000324	CcSEcCtD
Clomipramine—Anaphylactic shock—Methotrexate—urinary bladder cancer	4.04e-05	0.000324	CcSEcCtD
Clomipramine—Vision blurred—Doxorubicin—urinary bladder cancer	4.04e-05	0.000324	CcSEcCtD
Clomipramine—Convulsion—Epirubicin—urinary bladder cancer	4.02e-05	0.000322	CcSEcCtD
Clomipramine—Nausea—Etoposide—urinary bladder cancer	4.01e-05	0.000322	CcSEcCtD
Clomipramine—Hypertension—Epirubicin—urinary bladder cancer	4e-05	0.000321	CcSEcCtD
Clomipramine—Ill-defined disorder—Doxorubicin—urinary bladder cancer	3.98e-05	0.000319	CcSEcCtD
Clomipramine—Nervous system disorder—Methotrexate—urinary bladder cancer	3.97e-05	0.000318	CcSEcCtD
Clomipramine—Anaemia—Doxorubicin—urinary bladder cancer	3.97e-05	0.000318	CcSEcCtD
Clomipramine—Thrombocytopenia—Methotrexate—urinary bladder cancer	3.96e-05	0.000318	CcSEcCtD
Clomipramine—Chest pain—Epirubicin—urinary bladder cancer	3.95e-05	0.000317	CcSEcCtD
Clomipramine—Arthralgia—Epirubicin—urinary bladder cancer	3.95e-05	0.000317	CcSEcCtD
Clomipramine—Myalgia—Epirubicin—urinary bladder cancer	3.95e-05	0.000317	CcSEcCtD
Clomipramine—Agitation—Doxorubicin—urinary bladder cancer	3.94e-05	0.000316	CcSEcCtD
Clomipramine—Anxiety—Epirubicin—urinary bladder cancer	3.93e-05	0.000315	CcSEcCtD
Clomipramine—Skin disorder—Methotrexate—urinary bladder cancer	3.93e-05	0.000315	CcSEcCtD
Clomipramine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	3.92e-05	0.000314	CcSEcCtD
Clomipramine—Hyperhidrosis—Methotrexate—urinary bladder cancer	3.91e-05	0.000313	CcSEcCtD
Clomipramine—Discomfort—Epirubicin—urinary bladder cancer	3.9e-05	0.000313	CcSEcCtD
Clomipramine—Malaise—Doxorubicin—urinary bladder cancer	3.87e-05	0.00031	CcSEcCtD
Clomipramine—Dry mouth—Epirubicin—urinary bladder cancer	3.86e-05	0.00031	CcSEcCtD
Clomipramine—Vertigo—Doxorubicin—urinary bladder cancer	3.85e-05	0.000309	CcSEcCtD
Clomipramine—Anorexia—Methotrexate—urinary bladder cancer	3.85e-05	0.000309	CcSEcCtD
Clomipramine—Syncope—Doxorubicin—urinary bladder cancer	3.85e-05	0.000309	CcSEcCtD
Clomipramine—Leukopenia—Doxorubicin—urinary bladder cancer	3.84e-05	0.000308	CcSEcCtD
Clomipramine—Confusional state—Epirubicin—urinary bladder cancer	3.82e-05	0.000306	CcSEcCtD
Clomipramine—Palpitations—Doxorubicin—urinary bladder cancer	3.79e-05	0.000304	CcSEcCtD
Clomipramine—Oedema—Epirubicin—urinary bladder cancer	3.78e-05	0.000303	CcSEcCtD
Clomipramine—Anaphylactic shock—Epirubicin—urinary bladder cancer	3.78e-05	0.000303	CcSEcCtD
Clomipramine—Hypotension—Methotrexate—urinary bladder cancer	3.78e-05	0.000303	CcSEcCtD
Clomipramine—Loss of consciousness—Doxorubicin—urinary bladder cancer	3.77e-05	0.000302	CcSEcCtD
Clomipramine—Cough—Doxorubicin—urinary bladder cancer	3.74e-05	0.0003	CcSEcCtD
Clomipramine—Shock—Epirubicin—urinary bladder cancer	3.72e-05	0.000299	CcSEcCtD
Clomipramine—Convulsion—Doxorubicin—urinary bladder cancer	3.72e-05	0.000298	CcSEcCtD
Clomipramine—Nervous system disorder—Epirubicin—urinary bladder cancer	3.71e-05	0.000298	CcSEcCtD
Clomipramine—Thrombocytopenia—Epirubicin—urinary bladder cancer	3.71e-05	0.000297	CcSEcCtD
Clomipramine—Hypertension—Doxorubicin—urinary bladder cancer	3.7e-05	0.000297	CcSEcCtD
Clomipramine—Tachycardia—Epirubicin—urinary bladder cancer	3.69e-05	0.000296	CcSEcCtD
Clomipramine—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	3.68e-05	0.000295	CcSEcCtD
Clomipramine—Skin disorder—Epirubicin—urinary bladder cancer	3.68e-05	0.000295	CcSEcCtD
Clomipramine—Hyperhidrosis—Epirubicin—urinary bladder cancer	3.66e-05	0.000293	CcSEcCtD
Clomipramine—Insomnia—Methotrexate—urinary bladder cancer	3.66e-05	0.000293	CcSEcCtD
Clomipramine—Chest pain—Doxorubicin—urinary bladder cancer	3.65e-05	0.000293	CcSEcCtD
Clomipramine—Myalgia—Doxorubicin—urinary bladder cancer	3.65e-05	0.000293	CcSEcCtD
Clomipramine—Arthralgia—Doxorubicin—urinary bladder cancer	3.65e-05	0.000293	CcSEcCtD
Clomipramine—Anxiety—Doxorubicin—urinary bladder cancer	3.64e-05	0.000292	CcSEcCtD
Clomipramine—Paraesthesia—Methotrexate—urinary bladder cancer	3.63e-05	0.000291	CcSEcCtD
Clomipramine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	3.63e-05	0.000291	CcSEcCtD
Clomipramine—Discomfort—Doxorubicin—urinary bladder cancer	3.61e-05	0.000289	CcSEcCtD
Clomipramine—Anorexia—Epirubicin—urinary bladder cancer	3.61e-05	0.000289	CcSEcCtD
Clomipramine—Dyspnoea—Methotrexate—urinary bladder cancer	3.61e-05	0.000289	CcSEcCtD
Clomipramine—Somnolence—Methotrexate—urinary bladder cancer	3.6e-05	0.000288	CcSEcCtD
Clomipramine—Dry mouth—Doxorubicin—urinary bladder cancer	3.57e-05	0.000286	CcSEcCtD
Clomipramine—Dyspepsia—Methotrexate—urinary bladder cancer	3.56e-05	0.000285	CcSEcCtD
Clomipramine—Hypotension—Epirubicin—urinary bladder cancer	3.54e-05	0.000284	CcSEcCtD
Clomipramine—Confusional state—Doxorubicin—urinary bladder cancer	3.53e-05	0.000283	CcSEcCtD
Clomipramine—Decreased appetite—Methotrexate—urinary bladder cancer	3.52e-05	0.000282	CcSEcCtD
Clomipramine—Anaphylactic shock—Doxorubicin—urinary bladder cancer	3.5e-05	0.000281	CcSEcCtD
Clomipramine—Oedema—Doxorubicin—urinary bladder cancer	3.5e-05	0.000281	CcSEcCtD
Clomipramine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	3.49e-05	0.00028	CcSEcCtD
Clomipramine—Fatigue—Methotrexate—urinary bladder cancer	3.49e-05	0.00028	CcSEcCtD
Clomipramine—Pain—Methotrexate—urinary bladder cancer	3.46e-05	0.000277	CcSEcCtD
Clomipramine—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	3.45e-05	0.000276	CcSEcCtD
Clomipramine—Shock—Doxorubicin—urinary bladder cancer	3.45e-05	0.000276	CcSEcCtD
Clomipramine—Nervous system disorder—Doxorubicin—urinary bladder cancer	3.43e-05	0.000275	CcSEcCtD
Clomipramine—Thrombocytopenia—Doxorubicin—urinary bladder cancer	3.43e-05	0.000275	CcSEcCtD
Clomipramine—Insomnia—Epirubicin—urinary bladder cancer	3.42e-05	0.000274	CcSEcCtD
Clomipramine—Tachycardia—Doxorubicin—urinary bladder cancer	3.42e-05	0.000274	CcSEcCtD
Clomipramine—Skin disorder—Doxorubicin—urinary bladder cancer	3.4e-05	0.000273	CcSEcCtD
Clomipramine—Paraesthesia—Epirubicin—urinary bladder cancer	3.4e-05	0.000272	CcSEcCtD
Clomipramine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	3.39e-05	0.000271	CcSEcCtD
Clomipramine—Dyspnoea—Epirubicin—urinary bladder cancer	3.37e-05	0.000271	CcSEcCtD
Clomipramine—Somnolence—Epirubicin—urinary bladder cancer	3.36e-05	0.00027	CcSEcCtD
Clomipramine—Anorexia—Doxorubicin—urinary bladder cancer	3.34e-05	0.000268	CcSEcCtD
Clomipramine—Feeling abnormal—Methotrexate—urinary bladder cancer	3.33e-05	0.000267	CcSEcCtD
Clomipramine—Dyspepsia—Epirubicin—urinary bladder cancer	3.33e-05	0.000267	CcSEcCtD
Clomipramine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	3.31e-05	0.000265	CcSEcCtD
Clomipramine—Decreased appetite—Epirubicin—urinary bladder cancer	3.29e-05	0.000264	CcSEcCtD
Clomipramine—Hypotension—Doxorubicin—urinary bladder cancer	3.27e-05	0.000262	CcSEcCtD
Clomipramine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	3.27e-05	0.000262	CcSEcCtD
Clomipramine—Fatigue—Epirubicin—urinary bladder cancer	3.26e-05	0.000262	CcSEcCtD
Clomipramine—Constipation—Epirubicin—urinary bladder cancer	3.24e-05	0.00026	CcSEcCtD
Clomipramine—Pain—Epirubicin—urinary bladder cancer	3.24e-05	0.00026	CcSEcCtD
Clomipramine—Urticaria—Methotrexate—urinary bladder cancer	3.21e-05	0.000258	CcSEcCtD
Clomipramine—Abdominal pain—Methotrexate—urinary bladder cancer	3.2e-05	0.000256	CcSEcCtD
Clomipramine—Body temperature increased—Methotrexate—urinary bladder cancer	3.2e-05	0.000256	CcSEcCtD
Clomipramine—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	3.19e-05	0.000256	CcSEcCtD
Clomipramine—Insomnia—Doxorubicin—urinary bladder cancer	3.17e-05	0.000254	CcSEcCtD
Clomipramine—Paraesthesia—Doxorubicin—urinary bladder cancer	3.14e-05	0.000252	CcSEcCtD
Clomipramine—Dyspnoea—Doxorubicin—urinary bladder cancer	3.12e-05	0.00025	CcSEcCtD
Clomipramine—Feeling abnormal—Epirubicin—urinary bladder cancer	3.12e-05	0.00025	CcSEcCtD
Clomipramine—Somnolence—Doxorubicin—urinary bladder cancer	3.11e-05	0.00025	CcSEcCtD
Clomipramine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	3.09e-05	0.000248	CcSEcCtD
Clomipramine—Dyspepsia—Doxorubicin—urinary bladder cancer	3.08e-05	0.000247	CcSEcCtD
Clomipramine—Decreased appetite—Doxorubicin—urinary bladder cancer	3.04e-05	0.000244	CcSEcCtD
Clomipramine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	3.02e-05	0.000242	CcSEcCtD
Clomipramine—Fatigue—Doxorubicin—urinary bladder cancer	3.02e-05	0.000242	CcSEcCtD
Clomipramine—Urticaria—Epirubicin—urinary bladder cancer	3.01e-05	0.000241	CcSEcCtD
Clomipramine—Pain—Doxorubicin—urinary bladder cancer	2.99e-05	0.00024	CcSEcCtD
Clomipramine—Constipation—Doxorubicin—urinary bladder cancer	2.99e-05	0.00024	CcSEcCtD
Clomipramine—Abdominal pain—Epirubicin—urinary bladder cancer	2.99e-05	0.00024	CcSEcCtD
Clomipramine—Body temperature increased—Epirubicin—urinary bladder cancer	2.99e-05	0.00024	CcSEcCtD
Clomipramine—Hypersensitivity—Methotrexate—urinary bladder cancer	2.98e-05	0.000239	CcSEcCtD
Clomipramine—Asthenia—Methotrexate—urinary bladder cancer	2.9e-05	0.000233	CcSEcCtD
Clomipramine—Feeling abnormal—Doxorubicin—urinary bladder cancer	2.89e-05	0.000231	CcSEcCtD
Clomipramine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	2.86e-05	0.00023	CcSEcCtD
Clomipramine—Pruritus—Methotrexate—urinary bladder cancer	2.86e-05	0.000229	CcSEcCtD
Clomipramine—Hypersensitivity—Epirubicin—urinary bladder cancer	2.79e-05	0.000224	CcSEcCtD
Clomipramine—Urticaria—Doxorubicin—urinary bladder cancer	2.78e-05	0.000223	CcSEcCtD
Clomipramine—Body temperature increased—Doxorubicin—urinary bladder cancer	2.77e-05	0.000222	CcSEcCtD
Clomipramine—Abdominal pain—Doxorubicin—urinary bladder cancer	2.77e-05	0.000222	CcSEcCtD
Clomipramine—Diarrhoea—Methotrexate—urinary bladder cancer	2.77e-05	0.000222	CcSEcCtD
Clomipramine—Asthenia—Epirubicin—urinary bladder cancer	2.72e-05	0.000218	CcSEcCtD
Clomipramine—Pruritus—Epirubicin—urinary bladder cancer	2.68e-05	0.000215	CcSEcCtD
Clomipramine—Dizziness—Methotrexate—urinary bladder cancer	2.67e-05	0.000214	CcSEcCtD
Clomipramine—Diarrhoea—Epirubicin—urinary bladder cancer	2.59e-05	0.000208	CcSEcCtD
Clomipramine—Hypersensitivity—Doxorubicin—urinary bladder cancer	2.58e-05	0.000207	CcSEcCtD
Clomipramine—Vomiting—Methotrexate—urinary bladder cancer	2.57e-05	0.000206	CcSEcCtD
Clomipramine—Rash—Methotrexate—urinary bladder cancer	2.55e-05	0.000204	CcSEcCtD
Clomipramine—Dermatitis—Methotrexate—urinary bladder cancer	2.55e-05	0.000204	CcSEcCtD
Clomipramine—Headache—Methotrexate—urinary bladder cancer	2.53e-05	0.000203	CcSEcCtD
Clomipramine—Asthenia—Doxorubicin—urinary bladder cancer	2.51e-05	0.000201	CcSEcCtD
Clomipramine—Dizziness—Epirubicin—urinary bladder cancer	2.5e-05	0.000201	CcSEcCtD
Clomipramine—Pruritus—Doxorubicin—urinary bladder cancer	2.48e-05	0.000199	CcSEcCtD
Clomipramine—Vomiting—Epirubicin—urinary bladder cancer	2.41e-05	0.000193	CcSEcCtD
Clomipramine—Nausea—Methotrexate—urinary bladder cancer	2.4e-05	0.000193	CcSEcCtD
Clomipramine—Diarrhoea—Doxorubicin—urinary bladder cancer	2.4e-05	0.000192	CcSEcCtD
Clomipramine—Rash—Epirubicin—urinary bladder cancer	2.39e-05	0.000191	CcSEcCtD
Clomipramine—Dermatitis—Epirubicin—urinary bladder cancer	2.38e-05	0.000191	CcSEcCtD
Clomipramine—Headache—Epirubicin—urinary bladder cancer	2.37e-05	0.00019	CcSEcCtD
Clomipramine—Dizziness—Doxorubicin—urinary bladder cancer	2.32e-05	0.000186	CcSEcCtD
Clomipramine—Nausea—Epirubicin—urinary bladder cancer	2.25e-05	0.00018	CcSEcCtD
Clomipramine—Vomiting—Doxorubicin—urinary bladder cancer	2.23e-05	0.000179	CcSEcCtD
Clomipramine—Rash—Doxorubicin—urinary bladder cancer	2.21e-05	0.000177	CcSEcCtD
Clomipramine—Dermatitis—Doxorubicin—urinary bladder cancer	2.21e-05	0.000177	CcSEcCtD
Clomipramine—Headache—Doxorubicin—urinary bladder cancer	2.19e-05	0.000176	CcSEcCtD
Clomipramine—Nausea—Doxorubicin—urinary bladder cancer	2.08e-05	0.000167	CcSEcCtD
Clomipramine—HTR6—Signaling Pathways—CREBBP—urinary bladder cancer	6.75e-06	0.000138	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—CXCL8—urinary bladder cancer	6.68e-06	0.000137	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—IL2—urinary bladder cancer	6.68e-06	0.000137	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—IGF1—urinary bladder cancer	6.66e-06	0.000136	CbGpPWpGaD
Clomipramine—HTR6—Signaling by GPCR—EGFR—urinary bladder cancer	6.63e-06	0.000136	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR downstream signaling—RHOA—urinary bladder cancer	6.62e-06	0.000136	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—RHOA—urinary bladder cancer	6.61e-06	0.000135	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—RRM2—urinary bladder cancer	6.58e-06	0.000135	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—GPX1—urinary bladder cancer	6.53e-06	0.000134	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—CCND1—urinary bladder cancer	6.51e-06	0.000133	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—TYMP—urinary bladder cancer	6.51e-06	0.000133	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—ERCC2—urinary bladder cancer	6.41e-06	0.000131	CbGpPWpGaD
Clomipramine—HTR2A—GPCR downstream signaling—CXCL8—urinary bladder cancer	6.39e-06	0.000131	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—IL2—urinary bladder cancer	6.39e-06	0.000131	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—TERT—urinary bladder cancer	6.36e-06	0.00013	CbGpPWpGaD
Clomipramine—ADRA2A—Hemostasis—KRAS—urinary bladder cancer	6.35e-06	0.00013	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—S100B—urinary bladder cancer	6.34e-06	0.00013	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—MMP9—urinary bladder cancer	6.32e-06	0.000129	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—NQO1—urinary bladder cancer	6.3e-06	0.000129	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—CDKN1A—urinary bladder cancer	6.3e-06	0.000129	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—PTEN—urinary bladder cancer	6.28e-06	0.000129	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—NCOR1—urinary bladder cancer	6.27e-06	0.000128	CbGpPWpGaD
Clomipramine—HTR6—Signaling by GPCR—KRAS—urinary bladder cancer	6.26e-06	0.000128	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—EP300—urinary bladder cancer	6.22e-06	0.000127	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—CREBBP—urinary bladder cancer	6.16e-06	0.000126	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—NQO1—urinary bladder cancer	6.15e-06	0.000126	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	6.12e-06	0.000125	CbGpPWpGaD
Clomipramine—HTR2A—GPCR downstream signaling—IL2—urinary bladder cancer	6.11e-06	0.000125	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—RHOA—urinary bladder cancer	6.11e-06	0.000125	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	6.09e-06	0.000125	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—ENO2—urinary bladder cancer	6.09e-06	0.000125	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—IGF1—urinary bladder cancer	6.08e-06	0.000125	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	6.06e-06	0.000124	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—SRC—urinary bladder cancer	6.05e-06	0.000124	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—EGFR—urinary bladder cancer	6.05e-06	0.000124	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—MTHFR—urinary bladder cancer	6.03e-06	0.000123	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—RHOA—urinary bladder cancer	6.01e-06	0.000123	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—EP300—urinary bladder cancer	5.99e-06	0.000123	CbGpPWpGaD
Clomipramine—ALB—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	5.94e-06	0.000122	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	5.91e-06	0.000121	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—NAT2—urinary bladder cancer	5.88e-06	0.00012	CbGpPWpGaD
Clomipramine—ALB—Metabolism—GSTP1—urinary bladder cancer	5.86e-06	0.00012	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—FGFR3—urinary bladder cancer	5.84e-06	0.00012	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—SRC—urinary bladder cancer	5.83e-06	0.000119	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	5.82e-06	0.000119	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR downstream signaling—CXCL8—urinary bladder cancer	5.81e-06	0.000119	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—CXCL8—urinary bladder cancer	5.8e-06	0.000119	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—NQO1—urinary bladder cancer	5.8e-06	0.000119	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—KRAS—urinary bladder cancer	5.72e-06	0.000117	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—NCOR1—urinary bladder cancer	5.7e-06	0.000117	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—ESR1—urinary bladder cancer	5.67e-06	0.000116	CbGpPWpGaD
Clomipramine—ALB—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	5.67e-06	0.000116	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—ERBB2—urinary bladder cancer	5.65e-06	0.000116	CbGpPWpGaD
Clomipramine—ADRA2A—Hemostasis—TP53—urinary bladder cancer	5.64e-06	0.000116	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—RHOA—urinary bladder cancer	5.57e-06	0.000114	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR downstream signaling—IL2—urinary bladder cancer	5.55e-06	0.000114	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—IL2—urinary bladder cancer	5.54e-06	0.000113	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—TERT—urinary bladder cancer	5.52e-06	0.000113	CbGpPWpGaD
Clomipramine—ALB—Metabolism—TYMS—urinary bladder cancer	5.45e-06	0.000111	CbGpPWpGaD
Clomipramine—ADRA2A—Hemostasis—HRAS—urinary bladder cancer	5.4e-06	0.00011	CbGpPWpGaD
Clomipramine—ALB—Metabolism—GSTM1—urinary bladder cancer	5.38e-06	0.00011	CbGpPWpGaD
Clomipramine—ALB—Metabolism—NCOR1—urinary bladder cancer	5.38e-06	0.00011	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—CXCL8—urinary bladder cancer	5.36e-06	0.00011	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	5.33e-06	0.000109	CbGpPWpGaD
Clomipramine—HTR6—Signaling by GPCR—HRAS—urinary bladder cancer	5.32e-06	0.000109	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—CXCL8—urinary bladder cancer	5.28e-06	0.000108	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	5.26e-06	0.000108	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—MYC—urinary bladder cancer	5.22e-06	0.000107	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—ERBB2—urinary bladder cancer	5.16e-06	0.000106	CbGpPWpGaD
Clomipramine—ALB—Metabolism—GPX1—urinary bladder cancer	5.15e-06	0.000106	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—GSTP1—urinary bladder cancer	5.13e-06	0.000105	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—IL2—urinary bladder cancer	5.12e-06	0.000105	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—EGFR—urinary bladder cancer	5.11e-06	0.000105	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	5.09e-06	0.000104	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—RRM2—urinary bladder cancer	5.08e-06	0.000104	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—FGFR3—urinary bladder cancer	5.07e-06	0.000104	CbGpPWpGaD
Clomipramine—ALB—Metabolism—ERCC2—urinary bladder cancer	5.06e-06	0.000104	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—IL2—urinary bladder cancer	5.04e-06	0.000103	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—TERT—urinary bladder cancer	5.03e-06	0.000103	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—KRAS—urinary bladder cancer	5.01e-06	0.000103	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—CCND1—urinary bladder cancer	4.99e-06	0.000102	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—CREBBP—urinary bladder cancer	4.97e-06	0.000102	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—ESR1—urinary bladder cancer	4.92e-06	0.000101	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—NQO1—urinary bladder cancer	4.91e-06	0.000101	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—IGF1—urinary bladder cancer	4.91e-06	0.0001	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—CXCL8—urinary bladder cancer	4.89e-06	0.0001	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—TYMS—urinary bladder cancer	4.89e-06	0.0001	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—PPARG—urinary bladder cancer	4.89e-06	0.0001	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—EGFR—urinary bladder cancer	4.88e-06	0.0001	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—HRAS—urinary bladder cancer	4.86e-06	9.95e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—MMP9—urinary bladder cancer	4.85e-06	9.92e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	4.84e-06	9.9e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	4.83e-06	9.89e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	4.83e-06	9.89e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—CDKN1A—urinary bladder cancer	4.83e-06	9.89e-05	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—KRAS—urinary bladder cancer	4.83e-06	9.88e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—PTEN—urinary bladder cancer	4.82e-06	9.86e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—TYMS—urinary bladder cancer	4.77e-06	9.77e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.77e-06	9.76e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—MTHFR—urinary bladder cancer	4.76e-06	9.74e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—NCOR1—urinary bladder cancer	4.72e-06	9.65e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—GSTM1—urinary bladder cancer	4.72e-06	9.65e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	4.7e-06	9.63e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—ENO2—urinary bladder cancer	4.7e-06	9.63e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—CREBBP—urinary bladder cancer	4.7e-06	9.61e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—IL2—urinary bladder cancer	4.68e-06	9.57e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—GPX1—urinary bladder cancer	4.63e-06	9.47e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—KRAS—urinary bladder cancer	4.61e-06	9.44e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—FGFR3—urinary bladder cancer	4.61e-06	9.44e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—EP300—urinary bladder cancer	4.6e-06	9.41e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	4.56e-06	9.34e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—CCND1—urinary bladder cancer	4.56e-06	9.33e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	4.54e-06	9.3e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—GPX1—urinary bladder cancer	4.52e-06	9.24e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—TYMS—urinary bladder cancer	4.5e-06	9.2e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—RHOA—urinary bladder cancer	4.5e-06	9.2e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—ESR1—urinary bladder cancer	4.48e-06	9.17e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—SRC—urinary bladder cancer	4.47e-06	9.15e-05	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—TP53—urinary bladder cancer	4.45e-06	9.12e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	4.44e-06	9.1e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	4.44e-06	9.1e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—ERCC2—urinary bladder cancer	4.43e-06	9.08e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—MMP9—urinary bladder cancer	4.42e-06	9.06e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—CDKN1A—urinary bladder cancer	4.41e-06	9.03e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—PTEN—urinary bladder cancer	4.4e-06	9e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—CREBBP—urinary bladder cancer	4.32e-06	8.83e-05	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—TP53—urinary bladder cancer	4.29e-06	8.78e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	4.27e-06	8.74e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—IGF1—urinary bladder cancer	4.26e-06	8.72e-05	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—HRAS—urinary bladder cancer	4.26e-06	8.72e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—GPX1—urinary bladder cancer	4.26e-06	8.71e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—EGFR—urinary bladder cancer	4.24e-06	8.68e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—EP300—urinary bladder cancer	4.2e-06	8.59e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	4.18e-06	8.55e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—MTHFR—urinary bladder cancer	4.17e-06	8.53e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—ERBB2—urinary bladder cancer	4.16e-06	8.52e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.16e-06	8.51e-05	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—HRAS—urinary bladder cancer	4.1e-06	8.4e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	4.1e-06	8.39e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—SRC—urinary bladder cancer	4.08e-06	8.35e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—KRAS—urinary bladder cancer	4.01e-06	8.2e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—MYC—urinary bladder cancer	4.01e-06	8.2e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.96e-06	8.11e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—CXCL8—urinary bladder cancer	3.95e-06	8.08e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	3.93e-06	8.04e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—CREBBP—urinary bladder cancer	3.93e-06	8.04e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—HRAS—urinary bladder cancer	3.92e-06	8.03e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—EGFR—urinary bladder cancer	3.92e-06	8.02e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—RHOA—urinary bladder cancer	3.9e-06	7.99e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—IGF1—urinary bladder cancer	3.88e-06	7.94e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—EGFR—urinary bladder cancer	3.86e-06	7.9e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—PPARG—urinary bladder cancer	3.86e-06	7.9e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—PTGS2—urinary bladder cancer	3.85e-06	7.87e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—TYMS—urinary bladder cancer	3.81e-06	7.8e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—NQO1—urinary bladder cancer	3.79e-06	7.76e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—IL2—urinary bladder cancer	3.77e-06	7.72e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	3.76e-06	7.71e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	3.76e-06	7.71e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—CREBBP—urinary bladder cancer	3.71e-06	7.59e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—KRAS—urinary bladder cancer	3.7e-06	7.57e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—CCND1—urinary bladder cancer	3.68e-06	7.53e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—MYC—urinary bladder cancer	3.66e-06	7.48e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—KRAS—urinary bladder cancer	3.64e-06	7.46e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—ERBB2—urinary bladder cancer	3.61e-06	7.4e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—GPX1—urinary bladder cancer	3.61e-06	7.38e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—EGFR—urinary bladder cancer	3.58e-06	7.32e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—MMP9—urinary bladder cancer	3.57e-06	7.31e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—CDKN1A—urinary bladder cancer	3.56e-06	7.28e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—RHOA—urinary bladder cancer	3.55e-06	7.27e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—PTEN—urinary bladder cancer	3.55e-06	7.26e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	3.54e-06	7.25e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—PPARG—urinary bladder cancer	3.46e-06	7.09e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—CXCL8—urinary bladder cancer	3.43e-06	7.02e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—HRAS—urinary bladder cancer	3.41e-06	6.97e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—EP300—urinary bladder cancer	3.38e-06	6.93e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—PPARG—urinary bladder cancer	3.38e-06	6.92e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—KRAS—urinary bladder cancer	3.38e-06	6.91e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—PTEN—urinary bladder cancer	3.35e-06	6.86e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	3.33e-06	6.81e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	3.33e-06	6.81e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—SRC—urinary bladder cancer	3.29e-06	6.74e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—TP53—urinary bladder cancer	3.29e-06	6.73e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—ERBB2—urinary bladder cancer	3.29e-06	6.73e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—IL2—urinary bladder cancer	3.28e-06	6.7e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—CREBBP—urinary bladder cancer	3.25e-06	6.65e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—EP300—urinary bladder cancer	3.2e-06	6.55e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—CCND1—urinary bladder cancer	3.19e-06	6.54e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—PPARG—urinary bladder cancer	3.18e-06	6.52e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	3.16e-06	6.47e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—HRAS—urinary bladder cancer	3.15e-06	6.44e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—CXCL8—urinary bladder cancer	3.12e-06	6.38e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—MMP9—urinary bladder cancer	3.1e-06	6.35e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—HRAS—urinary bladder cancer	3.1e-06	6.34e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—CDKN1A—urinary bladder cancer	3.09e-06	6.32e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—PTEN—urinary bladder cancer	3.08e-06	6.31e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	3.06e-06	6.26e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—PTGS2—urinary bladder cancer	3.03e-06	6.21e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—TP53—urinary bladder cancer	3e-06	6.15e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—IL2—urinary bladder cancer	2.98e-06	6.1e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—MYC—urinary bladder cancer	2.95e-06	6.04e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—TYMS—urinary bladder cancer	2.94e-06	6.02e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—EP300—urinary bladder cancer	2.94e-06	6.02e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	2.91e-06	5.95e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	2.91e-06	5.95e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—CCND1—urinary bladder cancer	2.9e-06	5.95e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—EGFR—urinary bladder cancer	2.88e-06	5.9e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—HRAS—urinary bladder cancer	2.87e-06	5.88e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—SRC—urinary bladder cancer	2.86e-06	5.85e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—MMP9—urinary bladder cancer	2.82e-06	5.77e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—CDKN1A—urinary bladder cancer	2.81e-06	5.75e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—PTEN—urinary bladder cancer	2.8e-06	5.74e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—GPX1—urinary bladder cancer	2.78e-06	5.7e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	2.73e-06	5.59e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—KRAS—urinary bladder cancer	2.73e-06	5.58e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	2.72e-06	5.58e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—PPARG—urinary bladder cancer	2.7e-06	5.52e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—EP300—urinary bladder cancer	2.67e-06	5.47e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—PTGS2—urinary bladder cancer	2.66e-06	5.44e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—PTEN—urinary bladder cancer	2.65e-06	5.42e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—SRC—urinary bladder cancer	2.6e-06	5.32e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	2.59e-06	5.31e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	2.57e-06	5.26e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—MYC—urinary bladder cancer	2.56e-06	5.24e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—EP300—urinary bladder cancer	2.52e-06	5.17e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	2.51e-06	5.13e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—EGFR—urinary bladder cancer	2.51e-06	5.13e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—TP53—urinary bladder cancer	2.42e-06	4.96e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—PTEN—urinary bladder cancer	2.38e-06	4.86e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—KRAS—urinary bladder cancer	2.37e-06	4.84e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—MYC—urinary bladder cancer	2.33e-06	4.77e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—PTEN—urinary bladder cancer	2.32e-06	4.75e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—HRAS—urinary bladder cancer	2.32e-06	4.74e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—EGFR—urinary bladder cancer	2.28e-06	4.67e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—EP300—urinary bladder cancer	2.27e-06	4.64e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—EP300—urinary bladder cancer	2.21e-06	4.53e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—PTEN—urinary bladder cancer	2.19e-06	4.47e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—KRAS—urinary bladder cancer	2.15e-06	4.41e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	2.12e-06	4.34e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—TP53—urinary bladder cancer	2.1e-06	4.31e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—EP300—urinary bladder cancer	2.08e-06	4.27e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—PPARG—urinary bladder cancer	2.08e-06	4.26e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—HRAS—urinary bladder cancer	2.01e-06	4.12e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	2e-06	4.09e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—TP53—urinary bladder cancer	1.91e-06	3.92e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—PTEN—urinary bladder cancer	1.85e-06	3.79e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—HRAS—urinary bladder cancer	1.83e-06	3.75e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—EP300—urinary bladder cancer	1.77e-06	3.61e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.64e-06	3.35e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.43e-06	2.92e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.36e-06	2.79e-05	CbGpPWpGaD
